Molecular targets and the treatment of myeloid leukemia

被引:34
作者
Ikeda, A.
Shankar, D. B.
Watanabe, M.
Tamanoi, F.
Moore, T. B.
Sakamoto, K. M. [1 ]
机构
[1] Jonsson Comprehens Canc Ctr, Dept Pediat, Div Hematol Oncol, Gwyne Hazen Cherry Mem Labs, Los Angeles, CA USA
[2] Univ Calif Los Angeles, David Geffen Sch Med, Dept Pathol & Lab Med, Los Angeles, CA 90095 USA
[3] Univ Calif Los Angeles, Inst Mol Biol, Los Angeles, CA 90095 USA
[4] CALTECH, Div Biol, Pasadena, CA 91125 USA
[5] Univ Calif Los Angeles, Dept Microbiol Immunol & Mol Genet, Los Angeles, CA 90095 USA
关键词
targeted therapy; chromosomal translocations; apoptosis; cell cycle; small molecule inhibitors;
D O I
10.1016/j.ymgme.2006.03.011
中图分类号
R5 [内科学];
学科分类号
1002 [临床医学]; 100201 [内科学];
摘要
Leukemia is a multistep process involving accumulation of genetic alterations over time. These genetic mutations destroy the delicate balance between cell proliferation, differentiation, and apoptosis. Traditional approaches to treatment of leukemia involve chemotherapy, radiation, and bone marrow transplantation. In recent years, specific targeted therapies have been developed for the treatment of leukemia. The success of treatment of acute promyelocytic leukemia with All Trans Retinoic Acid (ATRA) and CML with imatinib have lead to increased efforts to identify targets that can be inhibited by small molecules for treatment of hernatological malignancies. In this review, we describe the current advances in the development of targeted therapy in acute myeloid leukemia. (c) 2006 Elsevier Inc. All rights reserved.
引用
收藏
页码:216 / 224
页数:9
相关论文
共 94 条
[1]
The t(11;20)(p15;q11) chromosomal translocation associated with therapy-related myelodysplastic syndrome results in an NUP98-TOP1 fusion [J].
Ahuja, HG ;
Felix, CA ;
Aplan, PD .
BLOOD, 1999, 94 (09) :3258-3261
[2]
Farnesyltransferase inhibitor tipifarnib is well tolerated, induces stabilization of disease, and inhibits farnesylation and oncogenic/tumor survival pathways in patients with advanced multiple myeloma [J].
Alsina, M ;
Fonseca, R ;
Wilson, EF ;
Belle, AN ;
Gerbino, E ;
Price-Troska, T ;
Overton, RM ;
Ahmann, G ;
Bruzek, LM ;
Adjei, AA ;
Kaufmann, SH ;
Wright, JJ ;
Sullivan, D ;
Djulbegovic, B ;
Cantor, AB ;
Greipp, PR ;
Dalton, WS ;
Sebti, SM .
BLOOD, 2004, 103 (09) :3271-3277
[3]
The signal transducer and activator of transcription STAT5b gene is a new partner of retinoic acid receptor α in acute promyelocytic-like leukaemia [J].
Arnould, C ;
Philippe, C ;
Bourdon, V ;
Grégoire, MJ ;
Berger, R ;
Jonveaux, P .
HUMAN MOLECULAR GENETICS, 1999, 8 (09) :1741-1749
[4]
Cloning and sequence analysis of four t(9;11) therapy-related leukemia breakpoints [J].
Atlas, M ;
Head, D ;
Behm, F ;
Schmidt, E ;
Zeleznik-Le, NJ ;
Roe, BA ;
Burian, D ;
Domer, PH .
LEUKEMIA, 1998, 12 (12) :1895-1902
[5]
Are all cancer genes equal? [J].
Bartek, J ;
Lukas, J .
NATURE, 2001, 411 (6841) :1001-1002
[6]
BEDI A, 1994, BLOOD, V83, P2038
[7]
BCR-ABL-MEDIATED INHIBITION OF APOPTOSIS WITH DELAY OF G2/M TRANSITION AFTER DNA-DAMAGE - A MECHANISM OF RESISTANCE TO MULTIPLE ANTICANCER AGENTS [J].
BEDI, A ;
BARBER, JP ;
BEDI, GC ;
ELDEIRY, WS ;
SIDRANSKY, D ;
VALA, MS ;
AKHTAR, AJ ;
HILTON, J ;
JONES, RJ .
BLOOD, 1995, 86 (03) :1148-1158
[8]
THE CHRONIC MYELOGENOUS LEUKEMIA SPECIFIC P210-PROTEIN IS THE PRODUCT OF THE BCR/ABL HYBRID GENE [J].
BEN-NERIAH, Y ;
DALEY, GQ ;
MESMASSON, AM ;
WITTE, ON ;
BALTIMORE, D .
SCIENCE, 1986, 233 (4760) :212-214
[9]
BLUTTERSSAWATZKI R, 1995, ANN HEMATOL, V70, P31
[10]
The translocation t(8;l6)(p11, p13) of acute myeloid leukaemia fuses a putative acetyltransferase to the CREB binding protein [J].
Borrow, J ;
Stanton, VP ;
Andresen, JM ;
Becher, R ;
Behm, FG ;
Chaganti, RSK ;
Civin, CI ;
Disteche, C ;
Dube, I ;
Frischauf, AM ;
Horsman, D ;
Mitelman, F ;
Volinia, S ;
Watmore, AE ;
Housman, DE .
NATURE GENETICS, 1996, 14 (01) :33-41